AUROPHARMA2022-01-012022-03-31in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2022-01-012022-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AUROPHARMA 2021-04-01 2022-03-31 2022-05-20 INR Millions Yearly true Cash Flow Indirect Single segment Pharmaceutical Products 2022-01-01 2022-03-31 Audited Standalone 28871700000.00 4133700000.00 33005400000.00 14207800000.00 11500000.00 218000000.00 3863800000.00 49100000.00 1012200000.00 5500900000.00 24863300000.00 8142100000.00 -747100000.00 7395000000.00 254100000.00 -880700000.00 -626600000.00 0.00 8021600000.00 0.00 0.00 0.00 0.00 8021600000.00 41000000.00 8062600000.00 8062600000.00 0.00 585900000.00 1 13.69 13.69 0.00 0.00 13.69 13.69 1. The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 30 May 2022. The statutory auditors have carried out audit of the above results for the quarter and year ended 31 March 2022. An unmodified report has been issued by them thereon. 3. The Company operates in only one segment viz., 'Pharmaceutical Products'. 4. Sales of standalone include exports of Rs.18,313.6 million for the current quarter (31 March 2021: Rs.35,628.6 million) and for the year ended 31 March 2022 of Rs.76,036.0 million (31 March 2021: Rs.137,277 million). 5. During the year the following units were transferred within the Group: The undertaking of Unit 10 located at Multiproduct Special Economic Zone, Naidupet, Mandal, SPSR Nellore District, Andhra Pradesh, transferred to its wholly-owned subsidiary APL Healthcare Limited through a slump sale for consideration of Rs.13,152.7 million, undertaking of Unit-4 of the Company located at Pashamylaram, Pattancheru Mandal, Sangareddy district, Telangana, transferred to Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company for consideration of Rs.9,383.2 million and undertaking of Unit-16 of the Company located at TSIIC, SEZ, Polepally Village, Jadcherla Mandal, Mahbubnagar district, Telangana, transferred to Wytells Pharma Private Limited, a wholly owned step-down subsidiary of the Company and 100% subsidiary of Eugia Pharma Specialities Limited for consideration of Rs.2,941.2 million. These transfers were approved by the Board of Directors of the Company. Due to the above transfers, the Company has recorded a capital gain tax of Rs.251.7 million and a reversal of deferred tax amounting to Rs.610.7 million. The Board of Directors of the Company as part of Company’s Verticalization of Vaccines Business, in its meeting held on 31 December 2021 approved the sale and transfer of undertaking of Unit 18 of the Company located at Survey No.69, 70, 71 & 72, Indrakaran Village, Kandi Mandal, Sangareddy District - 502203, Telangana, to Auro Vaccines Private Limited, a wholly owned subsidiary of the Company. This transfer is aimed at segregation of the vaccines business and subsidiarization of vaccines business in an special purpose vehicle. The slump sale of Unit 18 is effective from January 1, 2022 for a lumpsum consideration of Rs.3275.4 million (on a cash free basis). Unit 18 is yet to commence commercial operations. Single segment 2021-04-01 2022-03-31 Audited Standalone 112871400000.00 6709900000.00 119581300000.00 57839300000.00 168100000.00 455100000.00 16000400000.00 169400000.00 4152600000.00 23674500000.00 102459400000.00 17121900000.00 -747100000.00 16374800000.00 3797000000.00 -1969300000.00 1827700000.00 0.00 14547100000.00 0.00 0.00 0.00 0.00 14547100000.00 16900000.00 14564000000.00 14564000000.00 0.00 585900000.00 1 170587500000.00 24.83 24.83 0.00 0.00 24.83 24.83 Other expenses 5500900000.00 Other expenses 23674500000.00 152000000.00 11328300000.00 15923600000.00 0.00 1848400000.00 0.00 0.00 -54700000.00 0.00 -1044300000.00 0.00 43900000.00 0.00 4152600000.00 0.00 0.00 0.00 0.00 0.00 -125300000.00 4509900000.00 491000000.00 0.00 -274800000.00 0.00 0.00 747100000.00 117100000.00 0.00 27813000000.00 44187800000.00 0.00 0.00 0.00 6920700000.00 0.00 37267100000.00 0.00 0.00 0.00 17567500000.00 0.00 0.00 0.00 0.00 6434300000.00 6140600000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 32400000.00 0.00 0.00 0.00 0.00 7500000000.00 3634200000.00 0.00 0.00 4521900000.00 515000000.00 0.00 0.00 0.00 -16135100000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21541300000.00 0.00 209500000.00 2637000000.00 87600000.00 0.00 0.00 -24475400000.00 -3343400000.00 -10300000.00 -3353700000.00 3835800000.00 482100000.00